WednesdayMar 29, 2023 12:25 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in Upcoming Virtual Investor Event

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at an upcoming Virtual Investor GBM Spotlight Event. The online event is scheduled for April 4, 2023, at 4:30 p.m. ET. The event will include a live, moderated video webcast with members of CNS Pharmaceuticals management, including CEO John Climaco; the panel will also include key opinion leader, Michael Weller, MD. Weller is an acclaimed neuro-oncologist who currently serves as chair of the Department of Neurology at the University Hospital in Zurich,…

Continue Reading

MondayMar 27, 2023 2:38 pm

BioMedNewsBreaks – Titan Partners Group LLC Announces Appointment of Life-Sciences Expert Dr. David Sans

Titan Partners Group, a division of American Capital Partners LLC (“Titan Partners”), today announced that Dr. David Sans has joined the firm as head of healthcare. Dr. Sans will lead the team that covers companies in the biopharmaceuticals, diagnostics, medtech and specialty pharmaceuticals sectors. “We are excited to bring in David Sans to join Titan Partners and lead our healthcare practice as we continue to expand our footprint and capacity in this sector,” said Michael Sands, Titan Partners co-founder and partner. “David’s expertise in life sciences makes him a valuable addition to our team. Titan Partners is committed to building…

Continue Reading

MondayMar 27, 2023 10:59 am

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Fibromyalgia

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has filed a provisional patent application titled “Methods and Compositions for Pain Management.” The methods and compositions described in the patent application can be used in ameliorating pain, including chronic pain such as fibromyalgia, which is a chronic condition that occurs in approximately 2% of the United States general population. Fibromyalgia is the initial target indication for the company’s drug, SP-26. “This provisional patent application supports our multi-pronged strategy for advancing SP-26 into the clinic,” said Silo Pharma CEO…

Continue Reading

FridayMar 24, 2023 12:20 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 Variants

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. “BiondVax is seeing convincingly positive outcomes for preventing and arresting disease in COVID patients during an ongoing preclinical in vivo study, even as continually evolving variants are shutting down emergency-use authorization (‘EUA’)-approved avenues of treatment that may no longer be effective… However, BiondVax’s development of a nanosized antibody (‘NanoAb’), that to date has shown neutralization of all relevant Omicron subvariants, is generating excitement as a potential superior prophylactic approach to COVID prevention… At-risk groups, such…

Continue Reading

FridayMar 24, 2023 12:00 pm

BioMedNewsBreaks – Why Progressive Care Inc. (RXMD) Is ‘One to Watch’

Progressive Care (OTCQB: RXMD) is an organization based in Florida that, through its wholly owned subsidiaries PharmcoRx Pharmacy and ClearMetrX, offers personalized care services and technology to support the managed health care industries. “Progressive Care offers a wide range of innovative solutions to address the dispensing, delivery, dosing and reimbursement of clinically intensive, high-cost drugs. Progressive Care currently operates four pharmacies in Florida, which generate the majority of its revenue,” reads a recent article. “Pharmacy revenue is derived from dispensing medications, third-party administrative services to 340B-covered entities, and medication therapy management (‘MTM’) services. The company also provides customized management, patient…

Continue Reading

FridayMar 24, 2023 11:41 am

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Positioned as Frontrunner in Psychedelic Drugs Market

Silo Pharma (NASDAQ: SILO) is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. “Silo Pharma has distinguished itself amongst peers for its ground-breaking research into conditions such as post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s disease, and other rare neurological disorders. The company has recently entered into a number of studies designed to develop innovative solutions for previously underserved conditions,” a recent article reads. This comes as a recent study found that psychedelic drugs could show promise as a therapeutic alternative in treating drug-resistant depression. “What the study found was that psychedelics were increasingly able to access…

Continue Reading

FridayMar 24, 2023 11:24 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Poised to Enable Expedited Care for Heart Attack Patients

HeartBeam (NASDAQ: BEAT) is developing the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. “By applying a suite of proprietary algorithms to simplify vector electrocardiography (‘VECG’), the HeartBeam platform will enable patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized,…

Continue Reading

WednesdayMar 22, 2023 12:58 pm

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) to Attend Investor Summit

IGC Pharma (NYSE American: IGC) (aka India Globalization Capital Inc.) today announced that its Chief Executive Officer Ram Mukunda and Principle Financial Officer Claudia Grimaldi will attend the Investor Summit on Wednesday, March 29, 2023. According to the update, Mukunda and Grimaldi will deliver a virtual company presentation at 11:30 a.m. ET and be available for virtual one-on-one meetings throughout the day. Interested investors should visit https://ibn.fm/AiqIk to register for the webinar and view the live presentation. To view the full press release, visit https://ibn.fm/M3rGV About IGC Pharma Inc. IGC Pharma is a clinical stage biotechnology company developing advanced cannabinoid-based…

Continue Reading

WednesdayMar 22, 2023 12:47 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Subsidiary Receives Official Approval to Move Forward with Phase 1 Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, announced that its Australian entity, FSD Pharma Australia Pty Ltd., has been approved to move forward with a key phase 2 clinical trial. The approval comes from the Alfred Ethics Committee in Australia, and the trial is designed to evaluate FSD Pharma’s Lucid-201 as a novel drug candidate for the potential treatment of major depressive disorder (“MDD”). Lucid-Psych is being developed outside of Australia by Lucid Psycheceuticals Inc.,…

Continue Reading

WednesdayMar 22, 2023 10:08 am

BioMedNewsBreaks – Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) Tech Spotlighted in Article in Peer-Reviewed Translational Medicine Journal

Coeptis Therapeutics (NASDAQ: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, was spotlighted in the peer-reviewed “Journal of Translational Medicine.” The company’s SNAP-CAR technology was recognized in an article that detailed advances in modulating chimeric antigen receptor (“CAR”)-T cell activity for improved safety, efficacy and flexibility. SNAP-CAR is a multiantigen chimeric antigen receptor T cell technology that can be adapted to different cancer indications, including hematologic and solid tumors. Titled “Tuning CARs: Recent Advances In Modulating Chimeric Antigen Receptor (‘CAR’) T Cell Activity for Improved Safety, Efficacy and Flexibility,” the article outlined the efforts and collaborations that…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000